A novel inhaled Syk inhibitor blocks mast cell degranulation and early asthmatic response

Pharmacological Research

Volumn 99, Issue , 2015, Pages 116-124

  Ramis, Isabel ^a   Otal, Raquel ^a   Carreño, Cristina ^a   Domènech, Anna ^a   Eichhorn, Peter ^a   Orellana, Adelina ^a   Maldonado, Mónica ^a   De Alba, Jorge ^a   Prats, Neus ^a   Fernández, Joan Carles ^a   Vidal, Bernat ^a   Miralpeix, Montserrat ^a  

^a Almirall R and D Center Sant Feliu de Llobregat ^*  (Spain)

Author keywords

Asthma; Brown Norway rat; Early asthmatic response; Inhalation; Mast cells; Syk

Indexed keywords

1 [2 (2,5 DIAZABICYCLO[2.2.1]HEPT 2 YL)PYRIDIN 4 YL] N PYRAZIN 2 YL 1H INDAZOL 3 AMINE; ANTIASTHMATIC AGENT; METHYSERGIDE; MONTELUKAST; PHOSPHOTRANSFERASE; PROTEIN KINASE SYK; PROTEIN KINASE SYK INHIBITOR; UNCLASSIFIED DRUG; 1-(2-(2,5-DIAZABICYCLO(2.2.1)HEPT-2-YL)PYRIDIN-4-YL)-N-PYRAZIN-2-YL-1H-INDAZOL-3-AMINE; AZABICYCLO DERIVATIVE; INDAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE;

AIRWAY RESISTANCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; B LYMPHOCYTE ACTIVATION; BROWN NORWAY RAT; CELL ASSAY; CONTROLLED STUDY; DRUG HALF LIFE; DRUG TISSUE LEVEL; ENZYME ASSAY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; MALE; MAST CELL DEGRANULATION; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; B LYMPHOCYTE; CELL LINE; DEGRANULATION; DISEASE MODEL; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; MAST CELL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR RAT;

ADMINISTRATION, INHALATION; ANIMALS; ASTHMA; AZABICYCLO COMPOUNDS; B-LYMPHOCYTES; CELL DEGRANULATION; CELL LINE; DISEASE MODELS, ANIMAL; HUMANS; INDAZOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MAST CELLS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RATS; RATS, INBRED BN; RATS, WISTAR;

EID: 84935896446     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2015.05.011     Document Type: Article

References (30)

1. M. Turner, E. Schweighoffer, F. Colucci, J.P. Di Santo, and V.C. Tybulewicz Tyrosine kinase SYK: essential functions for immunoreceptor signaling Immunol. Today 21 2000 148 154
2. A. Mócsai, J. Ruland, and V.L.J. Tybulewicz The SYK tyrosine kinase: a crucial player in divers biological functions Nat. Rev. Immunol. 10 2010 387 402
3. M. Riccaboni, I. Bianchi, and P. Petrillo Spleen tyrosine kinases: biology, therapeutic targets and drugs Drug Discov. Today 15 2010 517 530
4. A.B. Rossi, E. Herlaar, S. Braselmann, S. Huynh, V. Taylor, R. Frances, S.D. Issakani, A. Argade, R. Singh, D.G. Payan, and E.S. Masuda Identification of the Syk kinase inhibitor R112 by a human mast cell screen J. Allergy Clin. Immunol. 118 2006 749 755
5. N. Yamamoto, K. Takeshita, M. Schichijo, T. Kokubo, M. Sato, K. Nakashima, M. Ishimore, H. Nagai, Y.F. Li, T. Yura, and K.B. Bacon The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]-nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents J. Pharmacol. Exp. Ther. 306 2003 1174 1181
6. S. Braselmann, V. Taylor, H. Zhao, S. Wang, C. Sylvain, M. Baluom, K. Qu, E. Herlaar, A. Lau, C. Young, B.R. Wong, S. Lovell, T. sun, G. Park, A. Argade, S. Jurcevic, P. Pine, R. Singh, E.B. Grossbard, D.G. Payan, and E.S. Masuda R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation J. Pharmacol. Exp. Ther. 319 2006 998 1008
7. J. Liddle, F.L. Atkinson, M.D. Barker, P.S. Carter, N.R. Curtis, R.P. Davis, C. Douault, M.C. Dickson, D. Elwes, N.S. Garton, M. Gray, T.G. Hayhow, C.I. Hobbs, E. Jones, S. Leach, K. Leavens, H.D. Lewis, S. McCleary, M. Neu, V.K. Patel, A.G.S. Preston, C. Ramirez-Molina, T.J. Shipley, P.A. Skone, N. Smithers, D.O. Somers, A.L. Walker, R.J. Watson, and G.G. Weingarten Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor Bioorg. Med. Chem. Lett. 21 2011 6188 6194
8. M.E. Weinblatt, A. Kavanaugh, M.C. Genovese, T.K. Musser, E.B. Grossbard, and D.B. Magilavy On oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis New Engl. J. Med. 363 2010 1303 1312
9. D.L. Scott Role of spleen tyrosine kinase inhibitors on the management of rheumatoid arthritis Drugs 71 2011 1121 1132
10. G. Coffey, A. Betz, F. DeGuzman, Y. Pak, M. Inagaki, D.C. Baker, S.J. Hollenbach, A. Pandey, and U. Sinha The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer J. Pharmacol. Exp. Ther. 351 2014 538 548
11. G. Coffey, F. DeGuzman, M. Inagaki, I. Park, S.M. Delaney, D. Ives, A. Betz, Z.J. Jia, A. Pandey, D. Baker, S.J. Hollenbach, D.R. Phillips, and U. Sinha Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis J. Pharmacol. Exp. Ther. 340 2012 350 359
12. K.S. Currie, J.E. Kropf, T. Lee, P. Blomgren, J. Xu, and Z. Zhao Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase J. Med. Chem. 57 2014 3856 3873
13. R. Singh, E.S. Masuda, and D.G. Payan Discovery and development of spleen tyrosine kinase (SYK) inhibitors J. Med. Chem. 55 2012 3614 3643
14. R. Allan, I. Jones, M. Bartley, D. Willbraham, and D. Singh A randomised, placebo controlled trial of the effect of an inhaled Syk inhibitor on allergen induced airway response in mild asthma Am. J. Respir. Crit. Care Med. 185 2012 A2774
15. A.S. Kirshenbaum, C. Akin, Y. Wu, M. Rottem, J.P. Goff, M.A. Beaven, V.K. Rao, and D.D. Metcalf Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcεRI and FcγRI Leuk. Res. 27 2003 677 682
16. D.J. Hele, M.A. Birell, S.E. Webber, M.L. Foster, and M. Belvisi Mediator involvement in antigen-induced bronchospasm and microvascular leakage in the airways of ovalbumin sensitized BN rats Br. J. Pharmacol. 132 2001 481 488
17. J. Zhang, M.L. Billingsley, R.L. Kincaid, and R.P. Siraganian Phosphorylation of Syk activation loop tyrosines is essential for Syk function J. Biol. Chem. 275 2000 35442 35447
18. R.E. Santing, C.G. Olymulder, J. Zaagsma, and H. Meurs Relationship among allergen-induced early and late phase airway obstruction, bronchial hyperreactivity and inflammation in conscious, unrestrained guinea pigs J. Allergy Clin. Immunol. 93 1994 1021 1030
19. H.-S. Cha, D.L. Boyle, T. Inoue, R. Schoot, P.P. Tak, P. Pine, and G.S. Firestein A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase m-mediated gene expression in synoviocytes J. Pharmacol. Exp. Ther. 317 2006 571 578
20. M.C. Alley, M.G. Hollingshead, C.M. Pacula-Cox, J.P. Carter, W.F. Jacob, and P.R. Pine Preclinical pharmacology evaluations of R406/R788, a multi-kinase inhibitor which exhibits unique, differential in vitro anticancer activity as well as in vivo antitumor efficacy following oral administration Proc. Am. Assoc. Cancer Res. 49 2008 1166 (#4889)
21. J. Zhang, T. Kimura, and R.P. Siraganian Mutations in the activation loop of tyrosines of protein tyrosine kinase Syk abrogate intracellular signalling but not kinase activity J. Immunol. 161 1998 4366 4374
22. A.E. Cooper, D. Ferguson, and K. Grime Optimisation of DMPK by the inhaled route: challenges and approaches Curr. Drug Metab. 13 2012 457 473
23. A. Tronde, B. Nordén, A. Marcher, A.-K. Wendel, H. Lennernäs, and U. Hultkvist Bengtsson Pulmonary absorption rate and bioavailability of drugs in vivo in rat: structure-absorption relationships and physicochemical profiling of inhaled drugs J. Pharm. Sci. 92 2003 1216 1233
24. S.T. Holgate, R.C. Benyon, P.H. Howarth, R. Agius, C. Hardy, C. Robinson, S.R. Durham, A.B. Kay, and M.K. Church Relationship between mediators release from human lung mast cells in vitro and in vivo Int. Arch. Allergy Appl. Immunol. 77 1985 47 56
25. R. Siraganian, J. Zhang, S. Katsuhiro, and K. Sada Protein tyrosine kinase Syk in mast cell signaling Mol. Immunol. 38 2001 1229 1233
26. R.L. Evans, A.T. Nials, R.G. Knowles, E.J. Kidd, W.R. Ford, and K.J. Broadley A comparison of antiasthma drugs between acute and chronic ovalbumin-challenged guinea-pig models of asthma Pulm. Pharmacol. Ther. 25 2012 453 464
27. L.Y. Moy, Y. Jia, M. Caniga, G. Lieber, M. Gil, and X. Fernandez Inhibition of spleen tyrosine kinase attenuates allergen-mediated airway constriction Am. J. Respir. Cell Mol. Biol. 49 2013 1085 1092
28. C. Carreño, A. Domènech, N. Prats, M. Miralpeix, and I. Ramis Characterization of a model of tracheal plasma extravasation in passively sensitized rats using anti-allergic and anti-inflammatory drugs by oral and intratracheal route Pulm. Pharmacol. Ther. 25 2012 87 93
29. H. Kurz, and B. Fichtl Binding of drugs to tissues Drug Metab. Rev. 14 1983 467 510
30. T. Murakami, and R. Yumoto Role of phosphatidylserine binding in tissue distribution of amine-containing basic compounds Expert Opin. Drug Metab. Toxicol. 7 2011 353 364